Wanbury quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	166	163	+1.5%
EBITDA	16.2	24.4	−33.6%
EBITDA margin	9.8%	15.0%	−5.2 pts
Profit before tax	4.6	13.6	−66.3%
Net profit	3.2	13.5	−76.0%
EPS	₹0.93	₹4.12	−77.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	166	165	162	160	163	172	133	161	131	139	145	144	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.4	0.2	0.2	0.2	0.3	1.8	0.8	1.6	0.9	0.9	0.7	0.8
	166	165	163	160	164	174	134	163	132	140	146	145
	74.0	62.9	66.5	70.7	72.8	75.9	60.9	76.8	64.2	66.9	63.9	75.7
	2.7	2.8	6.1	4.6	3.1	3.9	4.7	3.2	3.3	4.0	6.5	3.7
	2.3	−0.5	−3.8	−8.2	−0.5	4.5	−3.7	2.0	−1.2	−0.4	0.5	−3.0
	35.4	29.7	31.8	29.4	28.7	26.4	26.3	26.4	25.2	20.1	24.6	21.1
	8.0	8.1	7.3	7.1	7.5	9.0	10.2	10.1	7.6	7.5	8.3	7.7
	4.0	3.2	3.7	3.7	3.6	3.4	3.3	3.3	3.3	3.3	3.3	3.2
	35.0	39.7	35.1	37.8	34.7	31.6	31.3	32.8	28.7	30.7	28.9	29.7
	161	146	147	145	150	155	133	155	131	132	136	138
	16.2	29.9	26.7	25.8	24.4	29.6	13.9	20.0	11.0	18.2	21.1	17.3
	12.2	26.6	22.9	22.1	20.8	26.3	10.6	16.7	7.7	14.9	17.8	14.1
Profit
	4.6	18.8	15.9	15.2	13.6	19.1	1.3	8.2	1.0	8.3	10.3	7.2
	0.0	−3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	4.6	15.2	15.9	15.2	13.6	19.1	1.3	8.2	1.0	8.3	10.3	7.2
	0.0	0.6	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0
	1.3	−7.2	0.1	−0.0	0.1	−7.1	0.1	0.1	0.0	0.3	−0.0	−0.2
	1.3	−6.5	0.1	−0.0	0.1	−1.2	0.1	0.1	0.0	0.3	−0.0	−0.2
	3.2	21.7	15.8	15.2	13.5	20.3	1.2	8.0	1.0	8.1	10.3	7.4
	3.2	21.7	15.8	15.2	13.5	20.3	1.2	8.0	1.0	8.1	10.3	7.4
	−0.1	−0.2	−0.2	0.0	−0.2	0.0	−0.1	−0.0	−0.3	−0.5	0.0	0.4
	3.1	21.5	15.6	15.2	13.3	20.3	1.1	8.0	0.8	7.6	10.3	7.8
Per share
	₹0.93	₹7.33	₹4.52	₹4.58	₹4.12	₹6.18	₹0.76	₹2.44	₹0.32	₹2.47	₹3.14	₹2.25
	₹0.92	₹6.34	₹4.51	₹4.58	₹3.95	₹5.98	₹0.70	₹2.44	₹0.31	₹2.37	₹3.14	₹2.25
Other comprehensive income — detail
	−0.1	−0.2	−0.2	0.0	−0.2	0.0	—	—	—	—	—	—
	−0.2	−0.2	−0.3	−0.0	−0.2	0.1	−0.2	−0.2	−0.3	−0.7	0.1	0.6
	−0.0	0.0	−0.1	−0.0	−0.1	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	−0.1	−0.1	0.0	−0.3	0.0	0.2
	—	0.0	—	0.1	−0.1	−0.0	—	—	—	—	—	—
	0.0	0.0	0.0	0.0	−0.0	−0.0	—	—	—	—	—	—
Per share — as-filed variants
	₹0.93	₹7.33	₹4.52	₹4.58	₹4.12	₹6.18	₹0.38	₹2.44	₹0.32	₹2.47	₹3.14	₹2.25
	₹0.92	₹6.34	₹4.51	₹4.58	₹3.95	₹5.98	₹0.35	₹2.44	₹0.31	₹2.37	₹3.14	₹2.25
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.38	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.35	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00
Regulatory disclosures — filed alongside, not part of the P&L
	—	5.0	—	1.2	—	0.0	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	86.6	99.3	93.6	93.0	87.8	87.7	71.6	79.2	64.9	69.0	74.7	68.1
	52.3%	60.3%	57.6%	58.1%	53.8%	51.0%	53.6%	49.1%	49.5%	49.5%	51.3%	47.1%
Adjusted (ex-exceptional items) — derived
	4.6	18.8	15.9	15.2	13.6	19.1	1.3	8.2	1.0	8.3	10.3	7.2
	0.0	−3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	3.2	25.3	15.8	15.2	13.5	20.3	1.2	8.0	1.0	8.1	10.3	7.4
	₹0.93	₹8.55	₹4.52	₹4.58	₹4.12	₹6.18	₹0.76	₹2.44	₹0.32	₹2.47	₹3.14	₹2.25

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WANBURY₹174.16

Wanbury Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersAHCL ANUHPHR BAJAJHCARE THEMISMED ZIMLAB LINCOLN SIGACHI VALIANTLABMcap ₹609 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	144.5	145.5	139.4	131.1	161.2	133.5	172.0	163.2	160.1	162.4	164.6	165.6
Other Income	0.8	0.7	0.9	0.9	1.6	0.8	1.8	0.3	0.2	0.2	0.2	0.4
Total Income	145.2	146.2	140.3	132.1	162.8	134.3	173.8	163.5	160.3	162.6	164.8	165.9
Expenses
+ Cost of Materials Consumed	75.7	63.9	66.9	64.2	76.8	60.9	75.9	72.8	70.7	66.5	62.9	74.0
+ Purchases of Stock-in-Trade	3.7	6.5	4.0	3.3	3.2	4.7	3.9	3.1	4.6	6.1	2.8	2.7
+ Changes in Inventories	-3.0	0.5	-0.4	-1.2	2.0	-3.7	4.5	-0.5	-8.2	-3.8	-0.5	2.3
+ Employee Benefit Expense	21.1	24.6	20.1	25.2	26.4	26.3	26.4	28.7	29.4	31.8	29.7	35.4
+ Finance Costs	7.7	8.3	7.5	7.6	10.1	10.2	9.0	7.5	7.1	7.3	8.1	8.0
+ Depreciation & Amortisation	3.2	3.3	3.3	3.3	3.3	3.3	3.4	3.6	3.7	3.7	3.2	4.0
+ Other Expenses	29.7	28.9	30.7	28.7	32.8	31.3	31.6	34.7	37.8	35.1	39.7	35.0
Total Expenses	138.0	135.9	132.0	131.0	154.7	133.0	154.8	149.9	145.1	146.8	146.0	161.4
EBITDA	17.3	21.1	18.2	11.0	20.0	13.9	29.6	24.4	25.8	26.7	29.9	16.2
EBIT	14.1	17.8	14.9	7.7	16.7	10.6	26.3	20.8	22.1	22.9	26.6	12.2
Profit
PBT before Exceptional Items	7.2	10.3	8.3	1.0	8.2	1.3	19.1	13.6	15.2	15.9	18.8	4.6
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.6	0.0
Pretax Income	7.2	10.3	8.3	1.0	8.2	1.3	19.1	13.6	15.2	15.9	15.2	4.6
+ Current Tax	0.0	0.0	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.6	0.0
+ Deferred Tax	-0.2	-0.0	0.3	0.0	0.1	0.1	-7.1	0.1	-0.0	0.1	-7.2	1.3
Tax Expense	-0.2	-0.0	0.3	0.0	0.1	0.1	-1.2	0.1	-0.0	0.1	-6.5	1.3
Net Income	7.4	10.3	8.1	1.0	8.0	1.2	20.3	13.5	15.2	15.8	21.7	3.2
+ Net Income — Continuing Ops	7.4	10.3	8.1	1.0	8.0	1.2	20.3	13.5	15.2	15.8	21.7	3.2
+ Other Comprehensive Income	0.4	0.0	-0.5	-0.3	-0.0	-0.1	0.0	-0.2	0.0	-0.2	-0.2	-0.1
Total Comprehensive Income	7.8	10.3	7.6	0.8	8.0	1.1	20.3	13.3	15.2	15.6	21.5	3.1
Per Share
Basic EPS	2.25	3.14	2.47	0.32	2.44	0.76	6.18	4.12	4.58	4.52	7.33	0.93
Diluted EPS	2.25	3.14	2.37	0.31	2.44	0.70	5.98	3.95	4.58	4.51	6.34	0.92
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.0	-0.2	0.0	-0.2	-0.2	-0.1
+ Items NOT to be Reclassified to P&L	0.6	0.1	-0.7	-0.3	-0.2	-0.2	0.1	-0.2	-0.0	-0.3	-0.2	-0.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	-0.1	-0.0	-0.1	0.0	-0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.2	0.0	-0.3	0.0	-0.1	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	—	—	-0.0	-0.1	0.1	—	0.0	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	-0.0	-0.0	0.0	0.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.25	3.14	2.47	0.32	2.44	0.38	6.18	4.12	4.58	4.52	7.33	0.93
Diluted EPS — Continuing Operations	2.25	3.14	2.37	0.31	2.44	0.35	5.98	3.95	4.58	4.51	6.34	0.92
Basic EPS — Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.38	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.35	0.00	0.00	0.00	0.00	0.00	0.00
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	0.0	—	1.2	—	5.0	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	68.1	74.7	69.0	64.9	79.2	71.6	87.7	87.8	93.0	93.6	99.3	86.6
Gross Margin %	47.15	51.32	49.48	49.47	49.12	53.63	50.98	53.83	58.10	57.65	60.32	52.29
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	7.2	10.3	8.3	1.0	8.2	1.3	19.1	13.6	15.2	15.9	18.8	4.6
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.6	0.0
Net Income Adj (tax-effected)	7.4	10.3	8.1	1.0	8.0	1.2	20.3	13.5	15.2	15.8	25.3	3.2
EPS Adj	2.25	3.14	2.47	0.32	2.44	0.76	6.18	4.12	4.58	4.52	8.55	0.93
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	—	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	32.7	32.7	32.7	32.7	32.8	32.8	32.8	32.9	34.9	34.9	34.9	34.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Wanbury Q2 FY27 results date

Wanbury (NSE: WANBURY) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Standalone net profit was ₹3.2 crore, down 76.0% from ₹13.5 crore in Q1 FY26 and down 85.1% from ₹21.7 crore in Q4 FY26. Revenue from operations was ₹166 crore, up 1.5% year on year and up 0.6% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 13 November 2025
Q1 FY27 results (the latest): 11 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · standalone

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 28 Oct
Q1 FY27 net profit: ₹3.2 Cr−76.0% vs Q1 FY26−85.1% vs Q4 FY26
Q1 FY27 revenue: ₹166 Cr+1.5% vs Q1 FY26+0.6% vs Q4 FY26
Q1 FY27 operating margin: 7.4%−5.4 pts vs Q1 FY26−8.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹15.2 CrRevenue ₹160 Cr
Q1 FY27 EPS (basic): ₹0.93

Questions

When will Wanbury announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 13 November 2025.

What will Wanbury's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when standalone net profit was ₹15.2 crore and revenue from operations ₹160 crore. The latest quarter, Q1 FY27, had a net profit of ₹3.2 crore and revenue of ₹166 crore.

What were Wanbury's Q1 FY27 results?

Standalone net profit was ₹3.2 crore, down 76.0% from ₹13.5 crore in Q1 FY26 and down 85.1% from ₹21.7 crore in Q4 FY26. Revenue from operations was ₹166 crore, up 1.5% year on year and up 0.6% from the previous quarter.

How has Wanbury's profit changed over the last four quarters?

Net profit by quarter: ₹15.2 crore in Q2 FY26, ₹15.8 crore in Q3 FY26, ₹21.7 crore in Q4 FY26 and ₹3.2 crore in Q1 FY27. That is ₹55.9 crore over the four quarters, up 30.0% from ₹43 crore in the four quarters before. Revenue from operations: ₹160 crore, ₹162 crore, ₹165 crore and ₹166 crore.

What was Wanbury's net profit in FY26?

Standalone net profit was ₹66.1 crore in FY26 (April 2025–March 2026), up 116.6% from ₹30.5 crore in FY25. It was a profit of ₹30.4 crore in FY24 and a loss of ₹10.4 crore in FY23.

What was Wanbury's revenue in FY26?

Revenue from operations was ₹650 crore in FY26 (April 2025–March 2026), up 8.5% from ₹600 crore in FY25. It was ₹576 crore in FY24 and ₹500 crore in FY23: up 30.1% over three years, 9.2% a year on average.

Where do these Wanbury figures come from?

From Wanbury's own standalone results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Standalone figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.